硝苯地平与β-肾上腺素受体阻滞剂美托洛尔和阿替洛尔之间不存在药代动力学相互作用。
Lack of a pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers metoprolol and atenolol.
作者信息
Kendall M J, Jack D B, Laugher S J, Lobo J, Rolf Smith S
出版信息
Br J Clin Pharmacol. 1984 Sep;18(3):331-5. doi: 10.1111/j.1365-2125.1984.tb02472.x.
Abstract
Nifedipine, metoprolol and atenolol were administered orally to young, healthy volunteers. Each drug was given alone and nifedipine was also given with both beta-adrenoceptor blockers. Each drug was given for 3 days immediately before the study days. Plasma and urine drug concentrations were measured and the relevant pharmacokinetic parameters calculated. No pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers was revealed.
摘要
对年轻健康志愿者口服硝苯地平、美托洛尔和阿替洛尔。每种药物单独给药，硝苯地平也与两种β肾上腺素受体阻滞剂联合给药。每种药物在研究日前连续3天给药。测量血浆和尿液中的药物浓度，并计算相关的药代动力学参数。未发现硝苯地平和β肾上腺素受体阻滞剂之间存在药代动力学相互作用。
相似文献
1
Lack of a pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers metoprolol and atenolol.硝苯地平与β-肾上腺素受体阻滞剂美托洛尔和阿替洛尔之间不存在药代动力学相互作用。
Br J Clin Pharmacol. 1984 Sep;18(3):331-5. doi: 10.1111/j.1365-2125.1984.tb02472.x.
2
Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.硝苯地平对普萘洛尔、美托洛尔和阿替洛尔药代动力学及药效学影响的研究。
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):29S-35S. doi: 10.1111/j.1365-2125.1984.tb02425.x.
3
Interaction between the beta-adrenoceptor blockers metoprolol and atenolol with amitriptyline and their effects on oxidative liver metabolism.β-肾上腺素受体阻滞剂美托洛尔和阿替洛尔与阿米替林之间的相互作用及其对肝脏氧化代谢的影响。
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):65S-68S. doi: 10.1111/j.1365-2125.1984.tb02430.x.
4
Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine.美托洛尔、普萘洛尔和阿替洛尔与西咪替丁同时给药时的相互作用。
Klin Wochenschr. 1982 Nov 15;60(22):1401-7. doi: 10.1007/BF01716245.
5
The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol.西咪替丁预处理对阿替洛尔和美托洛尔生物利用度及处置的影响。
Br J Clin Pharmacol. 1982 Jul;14(1):67-72. doi: 10.1111/j.1365-2125.1982.tb04935.x.
6
Aiming for steady 24-hour plasma concentrations: a comparison of two calcium antagonist and beta-blocker combinations.
Blood Press Suppl. 1993;1:16-21.
7
Pharmacokinetics of atenolol and metoprolol administered together with piroxicam.阿替洛尔和美托洛尔与吡罗昔康联合给药的药代动力学。
Arch Pharm (Weinheim). 1987 Feb;320(2):103-7. doi: 10.1002/ardp.19873200203.
8
Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.地尔硫䓬对普萘洛尔、美托洛尔和阿替洛尔药代动力学的影响。
Eur J Clin Pharmacol. 1989;36(1):67-70. doi: 10.1007/BF00561026.
9
Pharmacokinetics and pharmacodynamics of verapamil in combination with atenolol, metoprolol and propranolol.维拉帕米与阿替洛尔、美托洛尔和普萘洛尔联合应用的药代动力学和药效学。
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):37S-44S. doi: 10.1111/j.1365-2125.1984.tb02426.x.
10
The effect of cimetidine on the relative cardioselectivity of atenolol and metoprolol in asthmatic patients.西咪替丁对哮喘患者阿替洛尔和美托洛尔相对心脏选择性的影响。
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):59S-64S. doi: 10.1111/j.1365-2125.1984.tb02429.x.
引用本文的文献
1
Plasma potassium changes in hypertensive patients undergoing oral surgery with local anesthetics containing epinephrine.接受含肾上腺素局部麻醉剂口腔手术的高血压患者的血浆钾变化。
Anesth Prog. 1997 Summer;44(3):106-9.
2
Pharmacokinetic interactions between felodipine and metoprolol.
Eur J Clin Pharmacol. 1987;31(5):575-8. doi: 10.1007/BF00606633.
3
The intra- and inter-subject variability of nifedipine pharmacokinetics in young volunteers.硝苯地平在年轻志愿者体内的药代动力学的个体内和个体间变异性。
Eur J Clin Pharmacol. 1986;30(1):57-60. doi: 10.1007/BF00614196.
4
Twelve hour (trough) plasma nifedipine concentrations during chronic treatment with nifedipine retard.硝苯地平缓释片长期治疗期间的12小时（谷值）血浆硝苯地平浓度。
Eur J Clin Pharmacol. 1987;32(4):347-9. doi: 10.1007/BF00543967.
5
Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.美托洛尔。对其药效学和药代动力学特性以及在高血压、缺血性心脏病和相关心血管疾病中的治疗效果的最新综述。
Drugs. 1986 May;31(5):376-429. doi: 10.2165/00003495-198631050-00002.
6
Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.硝苯地平。对其在缺血性心脏病、高血压及相关心血管疾病中的药效学、药代动力学特性及治疗效果的综述。
Drugs. 1985 Sep;30(3):182-274. doi: 10.2165/00003495-198530030-00002.
7
Nicardipine does not influence the pharmacokinetics and pharmacodynamics of atenolol.尼卡地平不影响阿替洛尔的药代动力学和药效学。
Br J Clin Pharmacol. 1990 Sep;30(3):499-500. doi: 10.1111/j.1365-2125.1990.tb03806.x.
8
Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations.高血压患者的药物相互作用。药代动力学、药效学及遗传学考量
Clin Pharmacokinet. 1990 Apr;18(4):295-317. doi: 10.2165/00003088-199018040-00003.
9
Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment.先前口服普萘洛尔治疗对静脉注射尼卡地平的动力学及血流动力学效应的影响。
Cardiovasc Drugs Ther. 1990 Dec;4(6):1525-32. doi: 10.1007/BF02026502.
10
Pharmacokinetic interactions with calcium channel antagonists (Part II).与钙通道拮抗剂的药代动力学相互作用（第二部分）。
Clin Pharmacokinet. 1991 Dec;21(6):448-60. doi: 10.2165/00003088-199121060-00005.
本文引用的文献
1
Bioavailability of atenolol formulations.阿替洛尔制剂的生物利用度。
Biopharm Drug Dispos. 1980 Oct-Dec;1(6):323-32. doi: 10.1002/bdd.2510010604.
2
Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol.连续输注利多卡因以及与普萘洛尔合用时，利多卡因清除率降低。
N Engl J Med. 1980 Aug 14;303(7):373-7. doi: 10.1056/NEJM198008143030705.
3
Interaction between oral propranolol and hydralazine.口服普萘洛尔与肼屈嗪之间的相互作用。
Clin Pharmacol Ther. 1980 Jun;27(6):726-32. doi: 10.1038/clpt.1980.103.
4
A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.常规释放与缓释美托洛尔的单剂量和多剂量药代动力学及药效学比较。
Eur J Clin Pharmacol. 1980 Feb;17(2):87-92. doi: 10.1007/BF00562615.
5
Identification of nifedipine metabolites and their determination by gas chromatography.
Chem Pharm Bull (Tokyo). 1980 Jan;28(1):1-7. doi: 10.1248/cpb.28.1.
6
Effects of treatment with nifedipine and metoprolol in essential hypertension.
Eur J Clin Pharmacol. 1982;21(5):389-90. doi: 10.1007/BF00542324.
7
Nifedipine and propranolol: a beneficial drug interaction.
Am J Med. 1981 Oct;71(4):676-82. doi: 10.1016/0002-9343(81)90238-2.
8
Clinical pharmacokinetics of metoprolol.美托洛尔的临床药代动力学
Clin Pharmacokinet. 1980 Nov-Dec;5(6):557-69. doi: 10.2165/00003088-198005060-00004.
9
Additive antianginal effect of verapamil in patients receiving propranolol.维拉帕米对接受普萘洛尔治疗患者的附加抗心绞痛作用。
Br Med J (Clin Res Ed). 1982 Apr 10;284(6322):1067-70. doi: 10.1136/bmj.284.6322.1067.
10
Lack of evidence for polymorphism in metoprolol metabolism.美托洛尔代谢中缺乏多态性的证据。
Br J Clin Pharmacol. 1983 Aug;16(2):188-90. doi: 10.1111/j.1365-2125.1983.tb04984.x.
Zotero 插件